0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Viewpoint | 
Peter C. Adamson, MD
JAMA Pediatr. 2013;167(10):886-887. doi:10.1001/jamapediatrics.2013.2488.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Editorial  | 
AREG and EREG as Predictive Biomarkers for RAS Wild-Type Colorectal Cancer Treated With Panitumumab A Fresh Approach to an Old Puzzle
Elizabeth C. Smyth, MB, BCh, MSc; Khurum Khan, MBBS; David Cunningham, FMedSci
JAMA Oncology
Original Investigation  | 
Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer
Jenny F. Seligmann, PhD; Faye Elliott, MSc; Susan D. Richman, PhD; et al.
JAMA Oncology
Viewpoint  | 
Addressing Skyrocketing Cancer Drug Prices Comes With Tradeoffs Pick Your Poison
Scott D. Ramsey, MD, PhD; Gary H. Lyman, MD, MPH; Rick Bangs, MBA, PMP
JAMA Oncology
Brief Report  | 
Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma
Elizabeth M. Swisher, MD; Maria I. Harrell, PhD; Barbara M. Norquist, MD; et al.